Plain-English translation of NCT05259553 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying blood markers—special signals in your blood that can predict whether you might develop dangerous blood clots—in people with newly diagnosed multiple myeloma. Researchers want to understand which patients are at highest risk for clots when they start myeloma treatment, and whether current blood-clot prevention medications might interact with myeloma drugs in ways that haven't been fully studied yet.
Right now, all newly diagnosed myeloma patients receive blood-clot prevention medication as part of their standard care, but doctors don't have reliable ways to identify who truly needs it or whether these preventive drugs might interfere with myeloma treatment. This trial aims to fill that gap by identifying the patients who are genuinely at risk.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood samples taken before you start myeloma treatment and then at specific times during your treatment. These blood samples will be analyzed to look for special markers that predict clot risk and to measure how your blood's clotting ability changes as you receive myeloma therapy. The study team will also monitor your health outcomes over time to see how these markers correlate with whether you actually develop blood clots.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
France